CORRECTION article

Front. Oncol., 22 January 2024

Sec. Gynecological Oncology

Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1357793

Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

  • FA

    Francesca Arezzo 1,2

  • GG

    Gaia Giannone 3*

  • DC

    Daniele Castaldo 4

  • GS

    Giulia Scotto 5

  • VT

    Valentina Tuninetti 6

  • MT

    Margherita Turinetto 5

  • MB

    Michele Bartoletti 7

  • SM

    Serafina Mammoliti 8

  • GA

    Grazia Artioli 9

  • GM

    Giorgia Mangili 10

  • VS

    Vanda Salutari 11

  • DL

    Domenica Lorusso 12

  • GC

    Gennaro Cormio 1,13

  • VL

    Vera Loizzi 1,13

  • CZ

    Claudio Zamagni 14

  • AS

    Antonella Savarese 15

  • MD

    Massimo Di Maio 6

  • GR

    Graziana Ronzino 16

  • CP

    Carmela Pisano 17

  • SP

    Sandro Pignata 17

  • GV

    Giorgio Valabrega 6

  • 1. Gynecologic Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy

  • 2. Department of Precision and Regenerative Medicine – Ionian Area, University of Bari “Aldo Moro”, Bari, Italy

  • 3. Department of Surgery and Cancer, Imperial College London, London, United Kingdom

  • 4. Segreteria Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) Group, Naples, Italy

  • 5. Department of Oncology, University of Turin, Turin, Italy

  • 6. Department of Oncology, Mauriziano Hospital, University of Turin, Turin, Italy

  • 7. Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy

  • 8. Ospedale Policlinico San Martino - Department of Medical Oncology, IRCCS, Genoa, Italy

  • 9. Oncologia Medica, Unità locale socio sanitaria n2 (ULSS2) Marca Trevigiana, Treviso, Italy

  • 10. Obstet-Gynecol Department, San Raffaele Scientific Institute, IRCCS, Milan, Italy

  • 11. Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

  • 12. Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli, and Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

  • 13. Interdisciplinar Department of Medicine, University of Bari “Aldo Moro”, Bari, Italy

  • 14. Azienda Ospedaliero-universitaria di Bologna, IRCCS, Bologna, Italy

  • 15. Department of Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy

  • 16. Department of Oncology, Ospedale “Vito Fazzi”, Lecce, Italy

  • 17. Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Napoli, Naples, Italy

In the published article, there was an error in affiliation 15. Instead of “Department of Oncology, Regina Elena National Cancer Institute, Rome, Italy”, it should be “Department of Oncology, IRCCS Regina Elena National Cancer Institute-Rome, Italy.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

endometrial cancer, molecular classification, immune checkpoint inhibitors, dostarlimab, pembrolizumab plus lenvatinib

Citation

Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S and Valabrega G (2024) Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors. Front. Oncol. 13:1357793. doi: 10.3389/fonc.2023.1357793

Received

18 December 2023

Accepted

19 December 2023

Published

22 January 2024

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2023

Updates

Copyright

*Correspondence: Gaia Giannone,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics